HIV Detail Information

Rilpivirine (ID: DG00269) Resistance Data of HIV
Drug Resistance Data Categorized by Their Corresponding Mechanisms
       Aberration of the Drug's Therapeutic Target (ADTT) Click to Show/Hide
Key Molecule: HIV1 Reverse transcriptase (HIV1 RT)
 Molecule Info 
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.K20R+p.V35I+p.K101KE+p.V106VI+p.D123E+p.I135T+p.K173T+p.Q174K+p.D177E+p.Y181I+p.M184V+p.G196E+p.T200K+p.Q207A+p.P243T+p.V245K+p.D256E+p.A272P+p.E291D+p.V292I+p.I293V+p.E297A
Missense mutation 22.8 Low-level resistance [1]
p.S48T+p.V90VI+p.K101E+p.Y115YF+p.Y181YC+p.M184I+p.R211N+p.K219KE+p.V245N+p.L283I+p.V292I+p.I293V
Missense mutation 26.7 Low-level resistance [1]
p.V35E+p.T39A+p.E138K+p.D177E+p.V179VI+p.Y181I+p.M184V+p.E194EK+p.G196EK+p.Q207E+p.R211K+p.V245K+p.I257L+p.K277R+p.T286A+p.I293V
Missense mutation 25.9 Low-level resistance [1]
p.V35I+p.L74V+p.L100I+p.K103N+p.M184V+p.Q207A+p.R211K+p.P225H+p.I293V
Missense mutation 15.6 Low-level resistance [1]
p.K20KR+p.A62AV+p.K65KN+p.V108VI+p.F171Y+p.D177E+p.I178IMV+p.M184MIV+p.T200A+p.Q207T+p.R211K+p.F227FC+p.L228LR+p.M230MI+p.L234LI+p.V245E+p.A272P
Missense mutation 10.4 Potential low-level resistance [1]
p.V35IM+p.G45X+p.V90I+p.K101KE+p.K122E+p.D123N+p.I135L+p.S162C+p.Q174K+p.V179I+p.Y181I+p.M184V+p.G196E+p.A272P+p.A288T
Missense mutation 32.1 Intermediate resistance [1]
p.V35I+p.V90I+p.K122E+p.D123N+p.I135L+p.S162C+p.Q174K+p.V179I+p.Y181I+p.M184V+p.G196E+p.A272P+p.A288T
Missense mutation 27.7 Low-level resistance [1]
p.K11T+p.V35I+p.E40K+p.K65R+p.T69T_X+p.I135L+p.D177E+p.I178M+p.V179VI+p.Y181C+p.Y188H+p.V189VI+p.G196E+p.K219KE+p.E291D+p.E297K
Missense mutation 19.2 Low-level resistance [1]
p.V35I+p.D67G+p.A98S+p.K101E+p.K122E+p.D123G+p.Y181C+p.M184I+p.T200A+p.K219E+p.M230L+p.V245E+p.K277R+p.I293V+p.P294A+p.E297K
Missense mutation 91 High-level resistance [1]
p.K20R+p.V35L+p.T39A+p.K122E+p.D123DN+p.I135R+p.K173E+p.Q174QR+p.D177E+p.V179I+p.Y181C+p.M184V+p.G196E+p.T200I+p.I202IV+p.R211K+p.K249KR+p.A288S+p.I293V
Missense mutation 10.1 Potential low-level resistance [1]
Resistant Drug Rilpivirine
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 GeneSeq assay; PhenoSense GT assay
Experiment for
Drug Resistance		 Viral load assay
Mechanism Description Amino acid changes in IN may contribute to drug resistance or sensitivity.
Key Molecule: HIV1 Reverse transcriptase (HIV1 RT)
 Molecule Info 
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.P4S+p.D67DN+p.T69N+p.K70KR+p.V90I+p.L100LI+p.K122E+p.D123N+p.I135IL+p.S162C+p.D177E+p.V179I+p.M184I+p.Y188L+p.T200A+p.R211K+p.K219E+p.M230MIL+p.L234LI+p.A272P+p.K277R+p.T286A+p.E297K
Missense mutation 100 High-level resistance [2]
p.K20R+p.V35L+p.M41L+p.K43E+p.D67N+p.T69N+p.K70R+p.K102Q+p.K103N+p.K122E+p.D123E+p.D177N+p.M184V+p.Y188L+p.G196E+p.I202V+p.R211T+p.T215F+p.D218E+p.K219Q+p.A272P+p.K277R+p.L283I+p.A288T+p.I293V+p.E297K+p.A304E
Missense mutation 30 Intermediate resistance [2]
p.T39AE+p.M41L+p.K43KR+p.E44D+p.L74LI+p.A98AG+p.K102KR+p.K103N+p.K122E+p.D123S+p.I135T+p.I142V+p.M184V+p.Y188L+p.H208Y+p.L210W+p.R211K+p.T215Y+p.L228H+p.R284K+p.T286A+p.P294T
Missense mutation 100 High-level resistance [2]
p.T69TN+p.K101P+p.K103N+p.I135V+p.I142V+p.Q145V+p.M184V+p.T200A+p.V245N+p.E248D+p.A272P+p.K275R+p.I293IV
Missense mutation 100 High-level resistance [2]
p.E28K+p.K32E+p.T39K+p.M41L+p.K43E+p.E44A+p.V60I+p.D67N+p.V75M+p.R83K+p.K102KR+p.K103S+p.V118I+p.K122E+p.I135T+p.V179T+p.Y181V+p.M184V+p.T200A+p.E203V+p.Q207E+p.H208Y+p.L210W+p.R211K+p.T215Y+p.D218E+p.K219E+p.L228H+p.Q242H+p.V245E+p.D256E+p.A272P+p.T286TI+p.A288T+p.I293V+p.E297T
Missense mutation 100 High-level resistance [2]
p.I5IV+p.E6K+p.K20KR+p.E44ED+p.D67N+p.T69D+p.V90VI+p.K102Q+p.K103N+p.K104KR+p.V118I+p.K122E+p.I142IV+p.V179I+p.Y181C+p.Y188L+p.T200A+p.Q207N+p.R211K+p.F214L+p.H221Y+p.I293V
Missense mutation 100 High-level resistance [2]
p.V35VI+p.T39TA+p.V90VI+p.L100I+p.Y115F+p.K122E+p.A158S+p.E169D+p.V179VI+p.M184V+p.Y188L+p.G196D+p.T200TA+p.Q207K+p.R211RK+p.T215F+p.K219E+p.L228H+p.V245E
Missense mutation 100 High-level resistance [2]
p.M41L+p.K43Q+p.V60I+p.D67N+p.T69D+p.L74LV+p.V75VIM+p.L100I+p.K103N+p.K122KE+p.I135L+p.E138G+p.I142V+p.I178L+p.M184V+p.G196E+p.Q207E+p.T215Y+p.V245E+p.A272P+p.V276VI+p.K277KR+p.T286A+p.E291A+p.I293V
Missense mutation 37 Intermediate resistance [2]
p.D67N+p.K70R+p.L74IV+p.L100I+p.K103N+p.D123E+p.I135T+p.K166R+p.G196E+p.T200A+p.I202V+p.T215I+p.K219E+p.L228LR+p.K277R+p.L283I+p.A288T+p.I293V+p.P294I+p.E297P
Missense mutation 53 Intermediate resistance [2]
p.D67G+p.S68G+p.K70R+p.K101Q+p.K122E+p.V179I+p.Y181I+p.I195T+p.Q207E+p.R211K+p.F214L+p.K219Q+p.H221Y+p.L228H+p.V245E+p.A272P+p.K277R+p.T286A+p.I293V
Missense mutation 100 High-level resistance [2]
p.K20R+p.D67N+p.K70R+p.K122E+p.I135V+p.E138A+p.S162C+p.M184MV+p.G190E+p.T200A+p.F214M+p.T215F+p.K219Q+p.L228H+p.V245E
Missense mutation 28 Low-level resistance [2]
p.K11K*+p.K20R+p.K64R+p.D67G+p.K70R+p.K101P+p.K103N+p.D123E+p.R172K+p.M184V+p.Q207E+p.R211K+p.F214L+p.K219E+p.T253TS
Missense mutation 100 High-level resistance [2]
p.V60I+p.K64Y+p.D67N+p.K70R+p.V90VI+p.K101P+p.T139M+p.M184V+p.G190A+p.K219Q+p.E224D+p.L228H+p.V245E
Missense mutation 100 High-level resistance [2]
p.M16MV+p.M41L+p.L74V+p.L100I+p.K103N+p.K122E+p.I135T+p.T139TA+p.K173KR+p.I178L+p.R211K+p.T215Y+p.A272P+p.I293V+p.E297A
Missense mutation 10 Potential low-level resistance [2]
p.T7A+p.M41L+p.K43E+p.D67N+p.K101Q+p.V106I+p.D123E+p.I135L+p.Y181I+p.M184V+p.Q197L+p.L210W+p.R211K+p.T215Y+p.A272P+p.I293V+p.L303P
Missense mutation 13 Potential low-level resistance [2]
p.V60I+p.D67G+p.S68G+p.K70KR+p.L74V+p.I135V+p.E138A+p.K173E+p.I178M+p.G190E+p.R211A+p.K219N+p.V245E+p.E248D+p.D250E+p.A272P+p.T286A
Missense mutation 100 High-level resistance [2]
p.M41L+p.L74V+p.I142V+p.T165L+p.E169D+p.Y181I+p.M184V+p.R211K+p.T215Y
Missense mutation 10 Potential low-level resistance [2]
p.M41L+p.E44D+p.D67N+p.T69D+p.K70KR+p.A98S+p.Y181I+p.L210W+p.R211K+p.T215Y+p.D218DE
Missense mutation 13 Potential low-level resistance [2]
Resistant Drug Rilpivirine
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Site-directed mutagenesis; Sanger sequencing assay
Experiment for
Drug Resistance		 PhenoSense assay
Mechanism Description Sixteen mutations at eight positions had a mean regression coefficient >=1.0 log10 (a contribution to decreased susceptibility of 10-fold or greater) for nevirapine, efavirenz, etravirine and/or rilpivirine: L100I, k101P, k103N/S, V106A/M, Y181C/I/V, Y188C/L, G190A/E/Q/S and F227C. With the exception of L100I and F227C, each mutation had a mean regression coefficient >=1.0 log10 for nevirapine. With the exception of k103S, V106A, Y181C/I/V and F227C, each had a mean regression coefficient >=1.0 log10 for efavirenz. Five mutations, k101P, Y181I/V, G190E and F227C, had a mean regression coefficient >=1.0 log10 for etravirine. Six mutations, L100I, k101P, Y181I/V, G190E and F227C, had a mean regression coefficient >= 1.0 log10 for rilpivirine.
Key Molecule: HIV1 Reverse transcriptase (HIV1 RT)
 Molecule Info 
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.K101P+p.K102Q+p.S162C+p.K277R+p.I293V
Missense mutation 12 Potential low-level resistance [3]
Resistant Drug Rilpivirine
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included K101P, K102Q, S162C, K277R, I293V.
Key Molecule: HIV1 Reverse transcriptase (HIV1 RT)
 Molecule Info 
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.K102Q+p.S162C+p.Y181I+p.K277R+p.I293V
Missense mutation 10 Potential low-level resistance [3]
Resistant Drug Rilpivirine
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included K102Q, S162C, Y181I, K277R, I293V.
Key Molecule: HIV1 Reverse transcriptase (HIV1 RT)
 Molecule Info 
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.K20R+p.K32KQ+p.M41L+p.E53ED+p.P59PS+p.L74V+p.I135T+p.Q145QR+p.Y181V+p.R211K+p.T215Y+p.K249R
Missense mutation 25 Low-level resistance [4]
Resistant Drug Rilpivirine
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included K20R, K32KQ, M41L, E53ED, P59PS, L74V, I135T, Q145QR, Y181V, R211K, T215Y, K249R.
Key Molecule: HIV1 Reverse transcriptase (HIV1 RT)
 Molecule Info 
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.K20R+p.K64KR+p.L74V+p.K103N+p.V108I+p.Y181C+p.M184V+p.T200A+p.R211K+p.H221Y+p.L228H+p.V245L+p.A272P+p.K277R+p.T286A
Missense mutation 14 Potential low-level resistance [4]
Resistant Drug Rilpivirine
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included K20R, K64KR, L74V, K103N, V108I, Y181C, M184V, T200A, R211K, H221Y, L228H, V245L, A272P, K277R, T286A.
Key Molecule: HIV1 Reverse transcriptase (HIV1 RT)
 Molecule Info 
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.K20R+p.V35I+p.K65KR+p.L74LV+p.K103N+p.K122E+p.Y181C+p.T200A+p.R211K+p.F227C+p.M230L+p.V245Q+p.I293V+p.E297A
Missense mutation 100 High-level resistance [4]
Resistant Drug Rilpivirine
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included K20R, V35I, K65KR, L74LV, K103N, K122E, Y181C, T200A, R211K, F227C, M230L, V245Q, I293V, E297A.
Key Molecule: HIV1 Reverse transcriptase (HIV1 RT)
 Molecule Info 
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.K20R+p.V35L+p.T39A+p.K101P+p.K103KR+p.K122E+p.I135R+p.D177E+p.I178M+p.T200TA+p.R211K+p.A272P+p.I293V
Missense mutation 33 Intermediate resistance [4]
Resistant Drug Rilpivirine
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included K20R, V35L, T39A, K101P, K103KR, K122E, I135R, D177E, I178M, T200TA, R211K, A272P, I293V.
Key Molecule: HIV1 Reverse transcriptase (HIV1 RT)
 Molecule Info 
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L100I+p.K102Q+p.K103N+p.S162C+p.K277R+p.I293V
Missense mutation 13.8 Potential low-level resistance [5]
Resistant Drug Rilpivirine
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L100I, K102Q, K103N, S162C, K277R, I293V.
Key Molecule: HIV1 Reverse transcriptase (HIV1 RT)
 Molecule Info 
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L100I+p.K102Q+p.K103S+p.S162C+p.K277R+p.I293V
Missense mutation 17.4 Low-level resistance [5]
Resistant Drug Rilpivirine
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L100I, K102Q, K103S, S162C, K277R, I293V.
Key Molecule: HIV1 Reverse transcriptase (HIV1 RT)
 Molecule Info 
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.M41L+p.A98S+p.K101P+p.K102Q+p.K103N+p.D123E+p.K166R+p.D177E+p.D192N+p.R211K+p.T215Y+p.V245K+p.K277R+p.R284K+p.T286A+p.E297K
Missense mutation 13 Potential low-level resistance [6]
Resistant Drug Rilpivirine
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included M41L, A98S, K101P, K102Q, K103N, D123E, K166R, D177E, D192N, R211K, T215Y, V245K, K277R, R284K, T286A, E297K.
Key Molecule: HIV1 Reverse transcriptase (HIV1 RT)
 Molecule Info 
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.M41L+p.K122E+p.E138G+p.D177E+p.I178L+p.L210W+p.R211K+p.T215Y+p.H221Y+p.F227L+p.M230L+p.V245M+p.I293V
Missense mutation 18 Low-level resistance [6]
Resistant Drug Rilpivirine
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included M41L, K122E, E138G, D177E, I178L, L210W, R211K, T215Y, H221Y, F227L, M230L, V245M, I293V.
Key Molecule: HIV1 Reverse transcriptase (HIV1 RT)
 Molecule Info 
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.M41L+p.K43Q+p.A62AV+p.T69S_ST+p.K101P+p.K103N+p.V118I+p.K122E+p.S162D+p.K166R+p.D177N+p.V179I+p.M184V+p.T200A+p.Q207E+p.L210F+p.R211K+p.T215Y+p.V245E+p.A272P+p.K277R+p.E291D+p.I293V
Missense mutation 88 High-level resistance [4]
Resistant Drug Rilpivirine
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included M41L, K43Q, A62AV, T69S_ST, K101P, K103N, V118I, K122E, S162D, K166R, D177N, V179I, M184V, T200A, Q207E, L210F, R211K, T215Y, V245E, A272P, K277R, E291D, I293V.
Key Molecule: HIV1 Reverse transcriptase (HIV1 RT)
 Molecule Info 
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.T39TP+p.D67N+p.K70R+p.V90I+p.K101P+p.K102R+p.K103N+p.K122E+p.I135V+p.Q151M+p.G196E+p.Q207K+p.R211A+p.K219Q+p.L228LH+p.E248D+p.I293V+p.E297A
Missense mutation 100 High-level resistance [4]
Resistant Drug Rilpivirine
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included T39TP, D67N, K70R, V90I, K101P, K102R, K103N, K122E, I135V, Q151M, G196E, Q207K, R211A, K219Q, L228LH, E248D, I293V, E297A.
Key Molecule: HIV1 Reverse transcriptase (HIV1 RT)
 Molecule Info 
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.V35I+p.M41L+p.D67G+p.L74I+p.L100I+p.K103R+p.K122E+p.V179D+p.M184V+p.I202V+p.R211K+p.T215Y+p.M230L+p.T240K
Missense mutation 92 High-level resistance [6]
Resistant Drug Rilpivirine
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included V35I, M41L, D67G, L74I, L100I, K103R, K122E, V179D, M184V, I202V, R211K, T215Y, M230L, T240K.
Key Molecule: HIV1 Reverse transcriptase (HIV1 RT)
 Molecule Info 
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.V60VI+p.D67G+p.S68G+p.T69N+p.K70R+p.K101P+p.K102Q+p.K103S+p.I142IV+p.D177E+p.I178L+p.M184V+p.T200A+p.T215V+p.K219E+p.I293V+p.E297K
Missense mutation 100 High-level resistance [7]
Resistant Drug Rilpivirine
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included V60VI, D67G, S68G, T69N, K70R, K101P, K102Q, K103S, I142IV, D177E, I178L, M184V, T200A, T215V, K219E, I293V, E297K.
Drug Sensitivity Data Categorized by Their Corresponding Mechanisms
       Aberration of the Drug's Therapeutic Target (ADTT) Click to Show/Hide
Key Molecule: HIV1 Reverse transcriptase (HIV1 RT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.V8VI+p.K20KR+p.V35I+p.D123E+p.I135T+p.K173T+p.Q174K+p.D177E+p.V179VD+p.G196E+p.T200K+p.Q207A+p.P243T+p.V245K+p.D256E+p.A272AP+p.T286TA+p.E291D+p.V292I+p.I293V+p.E297A
Missense mutation 0.8 Susceptible [1]
p.T39S+p.S48T+p.V60I+p.S68G+p.K102Q+p.K122KE+p.D123X+p.A158S+p.I178L+p.V179DE+p.I195IL+p.T200TA+p.R211K+p.I244V+p.V245E+p.A272P+p.K277KR+p.R284K+p.A288S+p.V292I+p.I293V+p.E297A
Missense mutation 1.9 Susceptible [1]
p.S48T+p.R211N+p.V245N+p.L283I+p.V292I+p.I293V
Missense mutation 1.3 Susceptible [1]
p.V35E+p.T39A+p.D177E+p.G196E+p.Q207E+p.R211K+p.V245K+p.I257L+p.K277R+p.T286A+p.I293V
Missense mutation 1.1 Susceptible [1]
p.V35T+p.E40ED+p.V60I+p.K122KE+p.I135V+p.S162A+p.K173T+p.Q174EK+p.P176PS+p.D177E+p.I178M+p.T200A+p.E204EK+p.Q207E+p.R211K+p.V245Q+p.A272P+p.K277R+p.K281R+p.T286A+p.I293V+p.P294T
Missense mutation 0.6 Susceptible [1]
p.V35M+p.K49KR+p.V60I+p.R83K+p.K122E+p.I135T+p.S162H+p.E248D+p.A272P+p.E297K
Missense mutation 0.9 Susceptible [1]
p.K11KR+p.V35I+p.R83K+p.T200TA+p.Q207A+p.R211K+p.I293V
Missense mutation 0.9 Susceptible [1]
p.A98S+p.K122E+p.A158AS+p.I159IV+p.S162SA+p.D177E+p.G196E+p.R211S+p.A272S+p.T286A+p.P294T
Missense mutation 0.7 Susceptible [1]
p.F171Y+p.D177E+p.I178IMV+p.T200A+p.Q207T+p.R211K+p.V245E+p.A272P+p.K277KR
Missense mutation 1.2 Susceptible [1]
p.V35I+p.K122E+p.D123N+p.I135L+p.S162C+p.K173N+p.Q174K+p.V179I+p.G196E+p.A272P+p.A288T
Missense mutation 0.7 Susceptible [1]
p.E6ED+p.V8VI+p.V35I+p.D86DE+p.K122P+p.D123E+p.I135L+p.T139I+p.D177E+p.Q207QK+p.R211RK+p.A272P+p.T286A+p.A288AG+p.I293IV
Missense mutation 1.5 Susceptible [1]
p.V35I+p.R83K+p.D177E+p.G196E+p.H208HY+p.L210LF+p.R211K+p.E291D+p.E297K
Missense mutation 0.8 Susceptible [1]
p.K20KR+p.V60I+p.S68G+p.I178ILM+p.G196E+p.T200TA+p.E248D+p.A272P+p.G273R+p.K275R+p.K281KR+p.V292I+p.I293V
Missense mutation 1 Susceptible [1]
p.V8I+p.K20R+p.A98AG+p.K101KE+p.K122KE+p.D123X+p.E138EK+p.I178IM+p.Y181YC+p.M184I+p.R211K+p.H221HY+p.V245I+p.E248ED+p.A272P+p.K277KR+p.I293V+p.P294S+p.E297R
Missense mutation 3.7 Susceptible [1]
p.V8I+p.K20R+p.T69TA+p.K122KE+p.D123X+p.I178IM+p.R211K+p.V245VI+p.E248ED+p.A272P+p.K277R+p.I293V+p.P294S+p.E297R
Missense mutation 0.8 Susceptible [1]
p.T39TA+p.T69TA+p.K82KR+p.R83RK+p.S162SN+p.P170PL+p.K173Q+p.I178M+p.T200A+p.Q207E+p.R211K+p.P225PL+p.L228LF+p.A272P+p.K277KR+p.L282LF+p.I293V+p.T296S+p.E297A
Missense mutation 0.9 Susceptible [1]
p.V35I+p.L80LF+p.A98S+p.K122E+p.T128TA+p.K166KR+p.I178IL+p.R211K+p.V245E+p.K277R+p.I293V+p.P294A+p.E297K
Missense mutation 0.8 Susceptible [1]
p.K20R+p.V35L+p.T39A+p.R83RK+p.K122E+p.I135R+p.K173E+p.D177E+p.V179I+p.G196E+p.T200I+p.I202V+p.R211K+p.V245VE+p.A288S+p.I293V
Missense mutation 0.6 Susceptible [1]
Sensitive Drug Rilpivirine
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 GeneSeq assay; PhenoSense GT assay
Experiment for
Drug Resistance		 Viral load assay
Mechanism Description Amino acid changes in IN may contribute to drug resistance or sensitivity.
Key Molecule: HIV1 Reverse transcriptase (HIV1 RT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E6D+p.V106I+p.V118I+p.I135V+p.T165I+p.T200A+p.F214L+p.V245R+p.D250E+p.A272P
Missense mutation 1.5 Susceptible [2]
p.M41L+p.K43Q+p.E44D+p.V60I+p.D67N+p.G93GR+p.K101H+p.V118I+p.K122P+p.D123E+p.I135T+p.I142V+p.D177E+p.I178IM+p.M184V+p.G190A+p.G196E+p.E203K+p.Q207E+p.L210W+p.R211K+p.T215Y+p.A272P+p.K277R
Missense mutation 0.6 Susceptible [2]
p.P4T+p.E6D+p.K20R+p.A33G+p.V60I+p.D67N+p.T69N+p.K70R+p.L74I+p.K101E+p.K103S+p.V118I+p.D123E+p.I135T+p.E138A+p.M184V+p.G190A+p.D192N+p.I195KR+p.G196E+p.E203K+p.R211A+p.F214L+p.K219Q+p.H221Y+p.I257L+p.A272P+p.K281R+p.E291D+p.E297K
Missense mutation 3.4 Susceptible [2]
p.V35I+p.R83K+p.S162A+p.I178IM+p.Q207E+p.I293V+p.E297A+p.L301M
Missense mutation 0.9 Susceptible [2]
p.K64KR+p.K102KR+p.D123E+p.K173X+p.P176PAT+p.D177DE+p.I178L+p.M184MV+p.Q197QEK+p.Q207E+p.R211K+p.V245VI+p.E248D+p.A272P+p.E297K
Missense mutation 1.3 Susceptible [2]
p.V35I+p.S48T+p.K101KR+p.K103N+p.V106VI+p.T139TA+p.P157PS+p.T200I+p.E203D+p.Q207E+p.R211RK+p.D250E+p.A272P+p.K275R+p.K277R+p.T286TA+p.I293IV
Missense mutation 0.9 Susceptible [2]
p.K20R+p.V35M+p.T69D+p.K102Q+p.K103N+p.K122E+p.E138G+p.S162SC+p.I178L+p.Q207E+p.A272P+p.K277R+p.L283I+p.I293V+p.E297A
Missense mutation 4.5 Susceptible [2]
p.P4T+p.E6K+p.K20R+p.T39TK+p.M41L+p.K43E+p.E44AD+p.D67N+p.L74I+p.K101E+p.V118I+p.K122E+p.S162A+p.V179F+p.Y181C+p.M184V+p.G190A+p.I195K+p.L210W+p.R211K+p.T215Y+p.K219N+p.V245K+p.I293V+p.E297A
Missense mutation 2.7 Susceptible [2]
p.K20R+p.K122E+p.R211K+p.V245M+p.G262GE+p.A272P+p.V292VI+p.I293IV+p.E297A
Missense mutation 1.1 Susceptible [2]
p.V35T+p.M41L+p.K43KN+p.V60I+p.K122E+p.K173KQ+p.D177EG+p.V179VI+p.Y188L+p.G196E+p.R211RK+p.T215D+p.V245E+p.I257L+p.K277R+p.I293V+p.E297R
Missense mutation 4 Susceptible [2]
p.P4S+p.E6D+p.K122E+p.D123N+p.I142V+p.S162C+p.D177E+p.I178L+p.R211K+p.A272P+p.I293V+p.E297R
Missense mutation 1.5 Susceptible [2]
p.K20R+p.V60I+p.K103N+p.D123E+p.I142V+p.Y181C+p.G196E+p.T200A+p.R211K+p.K219E+p.I293IM
Missense mutation 7.7 Susceptible [2]
p.E6K+p.V35I+p.T39TI+p.K102KQ+p.V106VI+p.K122E+p.I135IMV+p.I142M+p.S162C+p.R211K+p.K277R+p.A288S+p.I293V
Missense mutation 0.7 Susceptible [2]
p.K20R+p.I50IV+p.R83K+p.K166KR+p.K173X+p.Q174K+p.D177DE+p.I178L+p.V189VI+p.Q197QK+p.H198GE+p.Q207E+p.R211K+p.V245EQ+p.D250E+p.A272P+p.K277R
Missense mutation 1.5 Susceptible [2]
p.E6D+p.M41L+p.E44D+p.K49R+p.V60I+p.D67N+p.K70R+p.K103N+p.V108VI+p.D123E+p.I135T+p.M184V+p.T200I+p.I202V+p.T215V+p.K219E+p.P225PH+p.L228H+p.V245T+p.E248K+p.K249KR+p.I293V+p.E297A
Missense mutation 1.3 Susceptible [2]
p.V35T+p.T39TR+p.K122KE+p.D177E+p.K281R+p.T286A+p.I293IV+p.E297K
Missense mutation 1 Susceptible [2]
p.R83K+p.K101KE+p.K122E+p.D123DE+p.S162A+p.Q174G+p.G196E+p.T200A+p.Q207E+p.V245E+p.A272P+p.K277R+p.I293V
Missense mutation 2.7 Susceptible [2]
p.V90I+p.D123E+p.I202V+p.E204Q+p.Q207D+p.R211K+p.V245T+p.I293V+p.E297A
Missense mutation 2 Susceptible [2]
p.V35T+p.T39E+p.K46T+p.E53D+p.V60I+p.K64KR+p.K101Q+p.K104KR+p.K122E+p.D123S+p.I135K+p.K166R+p.K173A+p.D177E+p.T200A+p.Q207E+p.R211K+p.V245E+p.D250E+p.V254I+p.A272P+p.K277R+p.T286A+p.E291D+p.V292I+p.I293V
Missense mutation 1 Susceptible [2]
p.I135V+p.P176S+p.D177E+p.A272P+p.G285A+p.E297K
Missense mutation 1 Susceptible [2]
p.K13KR+p.K122E+p.I135T+p.S162C+p.M184V+p.G196E+p.K277R+p.I293V+p.E297A
Missense mutation 0.7 Susceptible [2]
p.V35T+p.M41L+p.L80I+p.K122E+p.D177E+p.Y188L+p.H198E+p.T215D+p.V245VE+p.I257IL+p.K277R+p.A288AT+p.I293V+p.E297R
Missense mutation 4.2 Susceptible [2]
p.K20R+p.V35M+p.T69D+p.K102Q+p.K122KE+p.E138EAG+p.S162C+p.I178L+p.M184MV+p.Q207E+p.A272P+p.K277R+p.L283I+p.I293V+p.E297A
Missense mutation 2 Susceptible [2]
p.K22R+p.V35M+p.S162C+p.I178L+p.V179I+p.Y181C+p.M184V+p.Y188L+p.T200A+p.Q207E+p.V245E+p.A272P+p.K277R
Missense mutation 9.8 Susceptible [2]
p.K20R+p.V60I+p.V90I+p.K101Q+p.K103N+p.V108I+p.I135V+p.I142V+p.D177E+p.M184I+p.T200I+p.R211K+p.T215D+p.A272P+p.V276I+p.L283I+p.I293V+p.E302EG
Missense mutation 1.4 Susceptible [2]
p.P4S+p.K122KE+p.D123E+p.E169D+p.I178L+p.T200A+p.I202IV+p.R211K+p.L246LP+p.E248D+p.A272P+p.T286TA+p.V292VI+p.I293V
Missense mutation 1.6 Susceptible [2]
p.V35VIL+p.K103N+p.K122E+p.K173Q+p.I178M+p.M184MV+p.T200TA+p.V245M+p.E248D+p.D250DE+p.T286A+p.A288S
Missense mutation 1.1 Susceptible [2]
p.P4PH+p.K20R+p.T39A+p.L74LI+p.R83K+p.V106VI+p.V179VI+p.M184V+p.E224D+p.V245E+p.T286A+p.P294PS+p.E297A
Missense mutation 0.6 Susceptible [2]
p.V60I+p.I135V+p.D177E+p.R211K+p.I244V+p.V245I+p.D250E+p.A272P+p.K277KR+p.E297V
Missense mutation 0.7 Susceptible [2]
p.S3C+p.E28R+p.K32E+p.V35M+p.M41L+p.L74I+p.R83K+p.A98G+p.K101E+p.K103N+p.V108I+p.S162A+p.I167IV+p.E169D+p.D177E+p.I178L+p.M184V+p.G196E+p.T200A+p.E203D+p.Q207E+p.L210W+p.R211K+p.T215Y+p.L228H+p.L260V+p.A272P+p.K281R+p.T286A+p.E297K
Missense mutation 8.2 Susceptible [2]
p.V35I+p.R83RK+p.T165TI+p.F171Y+p.T200A+p.I202V+p.V245M+p.A272P+p.K277R+p.T286A+p.P294Q+p.E297A
Missense mutation 0.6 Susceptible [2]
p.I135V+p.Y181C+p.M184V+p.G196E+p.T200A+p.Q207E+p.R211K+p.T215Y+p.V245K+p.K277R+p.E291D+p.E297K
Missense mutation 0.3 Susceptible [2]
p.K20KR+p.T27TS+p.V60I+p.R83K+p.K122KE+p.Q174L+p.I178IL+p.T200X+p.R211RK+p.V245E+p.L283LI+p.T286TA+p.I293V
Missense mutation 1 Susceptible [2]
p.P4S+p.V35VA+p.S48E+p.K101KE+p.K103KN+p.E169A+p.K173E+p.I178IM+p.I180IL+p.T200TA+p.V245VI+p.A272P
Missense mutation 3.3 Susceptible [2]
p.K122E+p.D123N+p.L210F+p.R211K+p.E248D+p.A272P+p.Q278H+p.I293V
Missense mutation 1.1 Susceptible [2]
p.I135T+p.T165TI+p.E169D+p.D177E+p.V179L+p.I202V+p.A272P+p.T296S+p.E297K
Missense mutation 0.5 Susceptible [2]
p.K20R+p.V35I+p.K122KE+p.I135T+p.E138K+p.R172K+p.T200V+p.R211RK+p.F214L+p.T286A+p.V292I+p.E297K
Missense mutation 1.1 Susceptible [2]
p.V35L+p.D67N+p.K70R+p.K101R+p.K103R+p.D177E+p.I178M+p.G190E+p.G196E+p.T200A+p.E204N+p.R211K+p.T215F+p.K219E+p.L228H+p.V245E+p.A272P+p.T286A+p.E297K
Missense mutation 7.3 Susceptible [2]
p.V60A+p.D67G+p.K103R+p.V118I+p.D123N+p.E138K+p.T165I+p.M184V+p.I202V+p.F214L+p.D250V+p.A272P+p.V276T+p.K277R+p.T286A+p.P294A
Missense mutation 0.3 Susceptible [2]
p.K20R+p.V35L+p.A62AV+p.S68SG+p.K70KN+p.V75T+p.R83K+p.S162N+p.T165I+p.F214L+p.H221Y+p.V245Q+p.E248N+p.D250E+p.G262GR+p.A272P+p.Q278H+p.K281R+p.T286A
Missense mutation 0.8 Susceptible [2]
p.D67N+p.K70R+p.I135T+p.S162C+p.Q174QE+p.Y181C+p.M184V+p.Q207KR+p.R211Q+p.K219Q+p.H221Y+p.I293V
Missense mutation 2.6 Susceptible [2]
p.Y181C+p.T200TA+p.F214L+p.H221Y+p.E291D+p.E297K
Missense mutation 2.2 Susceptible [2]
p.R83K+p.K122E+p.D123G+p.E138A+p.K166R+p.T200E+p.R211K+p.V245E+p.A272P+p.V276I+p.K277R+p.L283I+p.I293V+p.E297K
Missense mutation 1.9 Susceptible [2]
p.E28K+p.S68G+p.A98S+p.K101E+p.D123E+p.I135V+p.I142IT+p.R143RG+p.M184V+p.L210LW+p.R211K+p.T215Y+p.T286TA+p.E297A
Missense mutation 1 Susceptible [2]
p.E28K+p.V35M+p.M41L+p.T69N+p.K70R+p.R83K+p.K101E+p.K122P+p.S162C+p.D177E+p.M184V+p.I195L+p.V276T+p.K277R+p.E297EK
Missense mutation 1.3 Susceptible [2]
p.V35M+p.T39S+p.R83K+p.K122KE+p.D123E+p.E138A+p.I178IL+p.I202V+p.R211K+p.T286P+p.I293V+p.I329L+p.Q334E+p.M357T+p.A376T+p.E449D+p.D460N+p.S468P+p.H483N+p.L491P+p.Q524E+p.V559VI
Missense mutation 1.8 Susceptible [2]
p.K20R+p.K101E+p.K122E+p.M184V+p.G190A+p.D250E+p.A272P+p.P294Q+p.E302D
Missense mutation 2.8 Susceptible [2]
p.E6D+p.K103N+p.L109LS+p.D123E+p.I135T+p.S162A+p.M184IV+p.T200I+p.E204Q+p.Q207E+p.F214L+p.M230L+p.I244V+p.I293V
Missense mutation 3.6 Susceptible [2]
p.K11KRT+p.V60VI+p.W88C+p.D121H+p.K122E+p.I135T+p.D177E+p.Y181C+p.R211K+p.H221Y+p.V245E+p.V254VI+p.A272P+p.A288G+p.E291D+p.I293IV+p.E297K
Missense mutation 4.1 Susceptible [2]
p.E6D+p.K122E+p.E138A+p.I142T+p.D177E+p.I178M+p.I195L+p.I202V+p.R211K+p.V245I+p.A272P+p.L283I+p.I293V+p.E297A
Missense mutation 3.2 Susceptible [2]
p.K11KT+p.M41L+p.K43N+p.E44D+p.V75M+p.K101E+p.V118I+p.D123E+p.D177E+p.Y181C+p.E203D+p.Q207E+p.H208Y+p.L210W+p.R211K+p.T215Y+p.K219N+p.L228LR+p.A272P+p.I293V
Missense mutation 2.6 Susceptible [2]
p.M16MV+p.T69TN+p.V90I+p.L100I+p.K103N+p.D123E+p.I135V+p.G196E+p.P243S+p.V245E+p.E248DV+p.I293V+p.E297R
Missense mutation 9.8 Susceptible [2]
p.K20R+p.L74LV+p.Y115F+p.K122E+p.Y181C+p.M184V+p.R211K+p.F214L+p.H221Y+p.V241VM+p.I293V+p.E297A
Missense mutation 3.4 Susceptible [2]
p.T39TA+p.D67N+p.K70R+p.V90I+p.K101E+p.S162N+p.M184V+p.G190A+p.E203D+p.R211K+p.F214FL+p.K219H+p.E297A
Missense mutation 3.3 Susceptible [2]
p.I31V+p.D67N+p.T69N+p.D123E+p.E138K+p.D177E+p.M184V+p.G196E+p.K219Q+p.D237E+p.K277R+p.T286TA+p.I293V+p.E297A
Missense mutation 1.8 Susceptible [2]
p.M41L+p.K101H+p.I135T+p.M184V+p.G190A+p.L210W+p.R211K+p.T215Y+p.E248V+p.A272P+p.K277R+p.Q278QL
Missense mutation 1.1 Susceptible [2]
p.M41L+p.E44D+p.D67N+p.V118VI+p.I135T+p.S162C+p.R172K+p.Y188L+p.V189I+p.T200A+p.L210W+p.T215Y+p.D218E+p.K219R+p.V245E+p.A272P
Missense mutation 4.4 Susceptible [2]
p.K70KR+p.K122E+p.A158S+p.E169D+p.M184V+p.Y188L+p.G196D+p.Q207K+p.T215F+p.V245E
Missense mutation 5.5 Susceptible [2]
p.M41L+p.V60I+p.D67N+p.K101E+p.I135T+p.E138A+p.M184V+p.R211K+p.T215F+p.D218E+p.K219Q+p.K277KR+p.T286A+p.E297K
Missense mutation 1.4 Susceptible [2]
p.K20R+p.V60I+p.T69N+p.K70R+p.I142V+p.V179D+p.Y188L+p.R211K+p.V245I+p.K277R+p.A288S+p.I293V+p.E297A
Missense mutation 7.5 Susceptible [2]
p.S3SR+p.V35I+p.M41L+p.K43E+p.V60I+p.D67N+p.V75M+p.K101E+p.V118I+p.D121Y+p.K122E+p.Q174K+p.D177E+p.I178M+p.G190S+p.T200A+p.Q207A+p.L210W+p.R211K+p.T215Y+p.A272P+p.T286A+p.I293V
Missense mutation 0.5 Susceptible [2]
p.E40F+p.M41L+p.K43E+p.D67N+p.L74I+p.K101H+p.V118I+p.K122E+p.S162C+p.E169D+p.H208Y+p.L210W+p.R211K+p.T215Y+p.K219N+p.V245M+p.Q278QH+p.I293V
Missense mutation 0.7 Susceptible [2]
p.V35T+p.T39A+p.M41L+p.E44ED+p.V60I+p.D67N+p.T69D+p.V75M+p.F77L+p.V118I+p.K122E+p.I135T+p.E138K+p.S162X+p.M184V+p.H208HY+p.L210W+p.R211RK+p.T215Y+p.A272P+p.K277R+p.T286A
Missense mutation 0.3 Susceptible [2]
p.V35K+p.M41L+p.V60I+p.D67N+p.T69D+p.K70R+p.L74V+p.K101E+p.K104N+p.V118I+p.K122E+p.I135T+p.S162D+p.Y181C+p.M184V+p.G190S+p.F214L+p.T215F+p.K219Q+p.A272P
Missense mutation 6 Susceptible [2]
Sensitive Drug Rilpivirine
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Site-directed mutagenesis; Sanger sequencing assay
Experiment for
Drug Resistance		 PhenoSense assay
Mechanism Description Sixteen mutations at eight positions had a mean regression coefficient >=1.0 log10 (a contribution to decreased susceptibility of 10-fold or greater) for nevirapine, efavirenz, etravirine and/or rilpivirine: L100I, k101P, k103N/S, V106A/M, Y181C/I/V, Y188C/L, G190A/E/Q/S and F227C. With the exception of L100I and F227C, each mutation had a mean regression coefficient >=1.0 log10 for nevirapine. With the exception of k103S, V106A, Y181C/I/V and F227C, each had a mean regression coefficient >=1.0 log10 for efavirenz. Five mutations, k101P, Y181I/V, G190E and F227C, had a mean regression coefficient >=1.0 log10 for etravirine. Six mutations, L100I, k101P, Y181I/V, G190E and F227C, had a mean regression coefficient >= 1.0 log10 for rilpivirine.
Key Molecule: HIV1 Reverse transcriptase (HIV1 RT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.A62AV+p.K65R+p.K102R+p.K103N+p.A158T+p.M184V+p.T200E+p.R211K+p.L234I+p.A272S+p.I293V+p.P294S
Missense mutation 0.5 Susceptible [4]
Sensitive Drug Rilpivirine
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included A62AV, K65R, K102R, K103N, A158T, M184V, T200E, R211K, L234I, A272S, I293V, P294S.
Key Molecule: HIV1 Reverse transcriptase (HIV1 RT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.D123E+p.E138EK+p.S162C+p.I178L+p.Q207E+p.R211K+p.A272P+p.K277R+p.T286A+p.A288T+p.E297K
Missense mutation 3.2 Susceptible [4]
Sensitive Drug Rilpivirine
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included D123E, E138EK, S162C, I178L, Q207E, R211K, A272P, K277R, T286A, A288T, E297K.
Key Molecule: HIV1 Reverse transcriptase (HIV1 RT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.D67G+p.K70E+p.K102Q+p.K103KR+p.V106M+p.Y115F+p.D123E+p.I142V+p.S162C+p.E169D+p.K173Q+p.I178L+p.V179D+p.M184V+p.T200A+p.K277R+p.T286A+p.I293V
Missense mutation 0.7 Susceptible [4]
Sensitive Drug Rilpivirine
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included D67G, K70E, K102Q, K103KR, V106M, Y115F, D123E, I142V, S162C, E169D, K173Q, I178L, V179D, M184V, T200A, K277R, T286A, I293V.
Key Molecule: HIV1 Reverse transcriptase (HIV1 RT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.D67G+p.K70E+p.V90I+p.K102Q+p.I135T+p.S162F+p.I178IM+p.Y181C+p.T200E+p.R211QH+p.V245E+p.K277R+p.T286A+p.I293V+p.E297K
Missense mutation 2.2 Susceptible [4]
Sensitive Drug Rilpivirine
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included D67G, K70E, V90I, K102Q, I135T, S162F, I178IM, Y181C, T200E, R211QH, V245E, K277R, T286A, I293V, E297K.
Key Molecule: HIV1 Reverse transcriptase (HIV1 RT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.D67G+p.K70E+p.V90I+p.K122E+p.I135IT+p.S162F+p.I178IM+p.Y181C+p.T200E+p.R211HQ+p.V245E+p.A272P+p.K277R+p.T286A+p.E297K
Missense mutation 2.2 Susceptible [4]
Sensitive Drug Rilpivirine
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included D67G, K70E, V90I, K122E, I135IT, S162F, I178IM, Y181C, T200E, R211HQ, V245E, A272P, K277R, T286A, E297K.
Key Molecule: HIV1 Reverse transcriptase (HIV1 RT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.D67N+p.T69N+p.K70R+p.V90I+p.K103N+p.V118I+p.I135M
Missense mutation 1.4 Susceptible [8]
Sensitive Drug Rilpivirine
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included D67N, T69N, K70R, V90I, K103N, V118I, I135M.
Key Molecule: HIV1 Reverse transcriptase (HIV1 RT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.K101E+p.K102Q+p.S162C+p.M184I+p.K277R+p.I293V
Missense mutation 2.1 Susceptible [3]
Sensitive Drug Rilpivirine
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included K101E, K102Q, S162C, M184I, K277R, I293V.
Key Molecule: HIV1 Reverse transcriptase (HIV1 RT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.K101E+p.K102Q+p.S162C+p.M184V+p.K277R+p.I293V
Missense mutation 1.8 Susceptible [3]
Sensitive Drug Rilpivirine
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included K101E, K102Q, S162C, M184V, K277R, I293V.
Key Molecule: HIV1 Reverse transcriptase (HIV1 RT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.K101Q+p.K102Q+p.S162C+p.K277R+p.I293V
Missense mutation 1.6 Susceptible [3]
Sensitive Drug Rilpivirine
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included K101Q, K102Q, S162C, K277R, I293V.
Key Molecule: HIV1 Reverse transcriptase (HIV1 RT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.K102Q+p.E138A+p.S162C+p.K277R+p.I293V
Missense mutation 1.5 Susceptible [3]
Sensitive Drug Rilpivirine
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included K102Q, E138A, S162C, K277R, I293V.
Key Molecule: HIV1 Reverse transcriptase (HIV1 RT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.K102Q+p.E138G+p.S162C+p.K277R+p.I293V
Missense mutation 1.5 Susceptible [3]
Sensitive Drug Rilpivirine
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included K102Q, E138G, S162C, K277R, I293V.
Key Molecule: HIV1 Reverse transcriptase (HIV1 RT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.K102Q+p.E138Q+p.S162C+p.K277R+p.I293V
Missense mutation 2.9 Susceptible [3]
Sensitive Drug Rilpivirine
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included K102Q, E138Q, S162C, K277R, I293V.
Key Molecule: HIV1 Reverse transcriptase (HIV1 RT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.K102Q+p.E138R+p.S162C+p.K277R+p.I293V
Missense mutation 1.8 Susceptible [3]
Sensitive Drug Rilpivirine
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included K102Q, E138R, S162C, K277R, I293V.
Key Molecule: HIV1 Reverse transcriptase (HIV1 RT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.K102Q+p.K103N+p.S162C+p.K277R+p.I293V
Missense mutation 0.9 Susceptible [3]
Sensitive Drug Rilpivirine
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included K102Q, K103N, S162C, K277R, I293V.
Key Molecule: HIV1 Reverse transcriptase (HIV1 RT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.K102Q+p.K103R+p.S162C+p.K277R+p.I293V
Missense mutation 1.1 Susceptible [5]
Sensitive Drug Rilpivirine
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included K102Q, K103R, S162C, K277R, I293V.
Key Molecule: HIV1 Reverse transcriptase (HIV1 RT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.K102Q+p.K103R+p.S162C+p.V179D+p.K277R+p.I293V
Missense mutation 2.8 Susceptible [5]
Sensitive Drug Rilpivirine
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included K102Q, K103R, S162C, V179D, K277R, I293V.
Key Molecule: HIV1 Reverse transcriptase (HIV1 RT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.K102Q+p.K103S+p.S162C+p.K277R+p.I293V
Missense mutation 1.2 Susceptible [5]
Sensitive Drug Rilpivirine
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included K102Q, K103S, S162C, K277R, I293V.
Key Molecule: HIV1 Reverse transcriptase (HIV1 RT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.K102Q+p.S162C+p.H221Y+p.K277R+p.I293V
Missense mutation 0.8 Susceptible [3]
Sensitive Drug Rilpivirine
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included K102Q, S162C, H221Y, K277R, I293V.
Key Molecule: HIV1 Reverse transcriptase (HIV1 RT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.K102Q+p.S162C+p.M184V+p.K277R+p.I293V
Missense mutation 0.4 Susceptible [3]
Sensitive Drug Rilpivirine
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included K102Q, S162C, M184V, K277R, I293V.
Key Molecule: HIV1 Reverse transcriptase (HIV1 RT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.K102Q+p.S162C+p.Y181C+p.K277R+p.I293V
Missense mutation 1.5 Susceptible [3]
Sensitive Drug Rilpivirine
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included K102Q, S162C, Y181C, K277R, I293V.
Key Molecule: HIV1 Reverse transcriptase (HIV1 RT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.K122E+p.E138K+p.F214L+p.A272P+p.K277R+p.A376T+p.A400T
Missense mutation 2.3 Susceptible [9]
Sensitive Drug Rilpivirine
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included K122E, E138K, F214L, A272P, K277R, A376T, A400T.
Key Molecule: HIV1 Reverse transcriptase (HIV1 RT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.K122E+p.E138K+p.M184I+p.F214L+p.A272P+p.K277R+p.A376T+p.A400T
Missense mutation 2.5 Susceptible [9]
Sensitive Drug Rilpivirine
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included K122E, E138K, M184I, F214L, A272P, K277R, A376T, A400T.
Key Molecule: HIV1 Reverse transcriptase (HIV1 RT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.K122E+p.E138K+p.M184V+p.F214L+p.A272P+p.K277R+p.A376T+p.A400T
Missense mutation 2 Susceptible [9]
Sensitive Drug Rilpivirine
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included K122E, E138K, M184V, F214L, A272P, K277R, A376T, A400T.
Key Molecule: HIV1 Reverse transcriptase (HIV1 RT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.K122E+p.F214L+p.A272P+p.K277R+p.A376T+p.A400T
Missense mutation 1 Susceptible [9]
Sensitive Drug Rilpivirine
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included K122E, F214L, A272P, K277R, A376T, A400T.
Key Molecule: HIV1 Reverse transcriptase (HIV1 RT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.K122E+p.M184I+p.F214L+p.A272P+p.K277R+p.A376T+p.A400T
Missense mutation 1 Susceptible [9]
Sensitive Drug Rilpivirine
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included K122E, M184I, F214L, A272P, K277R, A376T, A400T.
Key Molecule: HIV1 Reverse transcriptase (HIV1 RT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.K122E+p.M184V+p.F214L+p.A272P+p.K277R+p.A376T+p.A400T
Missense mutation 0.8 Susceptible [9]
Sensitive Drug Rilpivirine
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included K122E, M184V, F214L, A272P, K277R, A376T, A400T.
Key Molecule: HIV1 Reverse transcriptase (HIV1 RT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.K20KR+p.K22R+p.V106I+p.I178L+p.R211K+p.F214FL+p.D250E+p.S251SN+p.K277R
Missense mutation 1.4 Susceptible [4]
Sensitive Drug Rilpivirine
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included K20KR, K22R, V106I, I178L, R211K, F214FL, D250E, S251SN, K277R.
Key Molecule: HIV1 Reverse transcriptase (HIV1 RT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.K20KR+p.T165TI+p.T200AV+p.E204EG+p.F214FL+p.K277R+p.T286A+p.A288S
Missense mutation 1 Susceptible [4]
Sensitive Drug Rilpivirine
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included K20KR, T165TI, T200AV, E204EG, F214FL, K277R, T286A, A288S.
Key Molecule: HIV1 Reverse transcriptase (HIV1 RT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.K20KR+p.V35I+p.K101H+p.I135V+p.S162C+p.D177E+p.I178IV+p.G190A+p.T200E+p.E203ED+p.R211K+p.I244IV+p.V245M+p.A272P+p.T286A+p.I293V+p.E297A
Missense mutation 1.8 Susceptible [4]
Sensitive Drug Rilpivirine
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included K20KR, V35I, K101H, I135V, S162C, D177E, I178IV, G190A, T200E, E203ED, R211K, I244IV, V245M, A272P, T286A, I293V, E297A.
Key Molecule: HIV1 Reverse transcriptase (HIV1 RT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.K64H+p.D67N+p.T69N+p.K70R+p.V90I+p.K103N+p.V118I+p.I135M+p.T215E+p.K219Q+p.A272P
Missense mutation 1.5 Susceptible [8]
Sensitive Drug Rilpivirine
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included K64H, D67N, T69N, K70R, V90I, K103N, V118I, I135M, T215E, K219Q, A272P.
Key Molecule: HIV1 Reverse transcriptase (HIV1 RT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L100I+p.K102Q+p.K103R+p.S162C+p.K277R+p.I293V
Missense mutation 1 Susceptible [5]
Sensitive Drug Rilpivirine
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L100I, K102Q, K103R, S162C, K277R, I293V.
Key Molecule: HIV1 Reverse transcriptase (HIV1 RT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L100I+p.K102Q+p.K103R+p.S162C+p.V179D+p.K277R+p.I293V
Missense mutation 6.8 Susceptible [5]
Sensitive Drug Rilpivirine
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L100I, K102Q, K103R, S162C, V179D, K277R, I293V.
Key Molecule: HIV1 Reverse transcriptase (HIV1 RT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L100I+p.K102Q+p.S162C+p.K277R+p.I293V
Missense mutation 0.7 Susceptible [5]
Sensitive Drug Rilpivirine
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L100I, K102Q, S162C, K277R, I293V.
Key Molecule: HIV1 Reverse transcriptase (HIV1 RT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.M41L+p.A62V+p.D67N+p.T69D+p.V75I+p.R83K+p.K103N+p.V108I+p.F116Y+p.D123E+p.Q151M+p.K166R+p.D177E+p.I202V+p.L210W+p.T215Y+p.M230L+p.A272P+p.I293V+p.E297K
Missense mutation 2.8 Susceptible [4]
Sensitive Drug Rilpivirine
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included M41L, A62V, D67N, T69D, V75I, R83K, K103N, V108I, F116Y, D123E, Q151M, K166R, D177E, I202V, L210W, T215Y, M230L, A272P, I293V, E297K.
Key Molecule: HIV1 Reverse transcriptase (HIV1 RT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.M41L+p.A98G+p.K101E+p.K122E+p.I135T+p.E138K+p.S162Y+p.Y181C+p.T200A+p.L210F+p.T215D+p.P243T+p.V245E+p.D250E+p.A272P+p.I274V+p.Q278H+p.K281R+p.T286A+p.A288S+p.K311R
Missense mutation 9.2 Susceptible [6]
Sensitive Drug Rilpivirine
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included M41L, A98G, K101E, K122E, I135T, E138K, S162Y, Y181C, T200A, L210F, T215D, P243T, V245E, D250E, A272P, I274V, Q278H, K281R, T286A, A288S, K311R.
Key Molecule: HIV1 Reverse transcriptase (HIV1 RT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.M41L+p.D67N+p.T69D+p.V75T+p.V118I+p.K122E+p.D123E+p.Q207E+p.L210W+p.T215Y+p.V245A+p.Q278H+p.I293V
Missense mutation 0.3 Susceptible [8]
Sensitive Drug Rilpivirine
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included M41L, D67N, T69D, V75T, V118I, K122E, D123E, Q207E, L210W, T215Y, V245A, Q278H, I293V.
Key Molecule: HIV1 Reverse transcriptase (HIV1 RT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.M41L+p.K43N+p.D67G+p.T69N+p.K70R+p.L74I+p.K103N+p.I142V+p.Y181C+p.M184V+p.G196E+p.I202V+p.T215F+p.K219Q+p.V245K+p.K277R+p.A288S+p.I293V
Missense mutation 1.1 Susceptible [8]
Sensitive Drug Rilpivirine
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included M41L, K43N, D67G, T69N, K70R, L74I, K103N, I142V, Y181C, M184V, G196E, I202V, T215F, K219Q, V245K, K277R, A288S, I293V.
Key Molecule: HIV1 Reverse transcriptase (HIV1 RT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.N57ND+p.V60I+p.D67DN+p.K70GR+p.V118VI+p.K166KR+p.M184V+p.E203EK+p.R211RK+p.F214L+p.K219Q+p.I293V
Missense mutation 0.3 Susceptible [4]
Sensitive Drug Rilpivirine
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included N57ND, V60I, D67DN, K70GR, V118VI, K166KR, M184V, E203EK, R211RK, F214L, K219Q, I293V.
Key Molecule: HIV1 Reverse transcriptase (HIV1 RT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.P4S+p.V35T+p.V60I+p.D67N+p.K70G+p.K102Q+p.V118I+p.D123E+p.E138A+p.S162C+p.K173KR+p.Q174K+p.M184V+p.G196E+p.Q207E+p.K219Q+p.D237E+p.V245M+p.S251N+p.K277R+p.I293IV+p.E297A+p.R358KT+p.D364DE
Missense mutation 0.6 Susceptible [4]
Sensitive Drug Rilpivirine
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included P4S, V35T, V60I, D67N, K70G, K102Q, V118I, D123E, E138A, S162C, K173KR, Q174K, M184V, G196E, Q207E, K219Q, D237E, V245M, S251N, K277R, I293IV, E297A, R358KT, D364DE.
Key Molecule: HIV1 Reverse transcriptase (HIV1 RT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.R211K+p.F214FL
Missense mutation 0.6 Susceptible [4]
Sensitive Drug Rilpivirine
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included R211K, F214FL.
Key Molecule: HIV1 Reverse transcriptase (HIV1 RT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.R83K+p.I135T+p.S162Y+p.I178L+p.D192DN+p.T200TA+p.R211RG+p.F214L+p.I244V+p.V245E+p.A272P+p.K277R+p.I293V
Missense mutation 0.6 Susceptible [4]
Sensitive Drug Rilpivirine
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included R83K, I135T, S162Y, I178L, D192DN, T200TA, R211RG, F214L, I244V, V245E, A272P, K277R, I293V.
Key Molecule: HIV1 Reverse transcriptase (HIV1 RT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.T39A+p.D67N+p.T69N+p.K70R+p.K103R+p.I135L+p.F214L+p.K219Q+p.A272P
Missense mutation 0.6 Susceptible [8]
Sensitive Drug Rilpivirine
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included T39A, D67N, T69N, K70R, K103R, I135L, F214L, K219Q, A272P.
Key Molecule: HIV1 Reverse transcriptase (HIV1 RT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.T39A+p.K64N+p.D67N+p.T69N+p.K70R+p.K103R+p.I135L+p.F214L+p.K219Q+p.A272P
Missense mutation 0.3 Susceptible [8]
Sensitive Drug Rilpivirine
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included T39A, K64N, D67N, T69N, K70R, K103R, I135L, F214L, K219Q, A272P.
Key Molecule: HIV1 Reverse transcriptase (HIV1 RT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.T39TA+p.K70E+p.K102Q+p.D123E+p.I142IM+p.S162C+p.M184V+p.R211K+p.K277R+p.T286A+p.V292I+p.I293V+p.E297K+p.A304E+p.S322SA
Missense mutation 0.5 Susceptible [4]
Sensitive Drug Rilpivirine
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included T39TA, K70E, K102Q, D123E, I142IM, S162C, M184V, R211K, K277R, T286A, V292I, I293V, E297K, A304E, S322SA.
Key Molecule: HIV1 Reverse transcriptase (HIV1 RT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.V35I+p.R83K+p.K103N+p.I135T+p.E138G+p.K166KR+p.T200TA+p.H208HY+p.R211K+p.I244V+p.D250E+p.A272P+p.I293V
Missense mutation 1.2 Susceptible [4]
Sensitive Drug Rilpivirine
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included V35I, R83K, K103N, I135T, E138G, K166KR, T200TA, H208HY, R211K, I244V, D250E, A272P, I293V.
Key Molecule: HIV1 Reverse transcriptase (HIV1 RT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.V35IM+p.T39TA+p.R83K+p.K102KQ+p.K103N+p.D123E+p.S162C+p.D177E+p.I178R+p.V179F+p.R211RK+p.V245EQ+p.D250E+p.K277R+p.T286A+p.I293V+p.M357AS+p.E370ED+p.T377TMI
Missense mutation 1.2 Susceptible [4]
Sensitive Drug Rilpivirine
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included V35IM, T39TA, R83K, K102KQ, K103N, D123E, S162C, D177E, I178R, V179F, R211RK, V245EQ, D250E, K277R, T286A, I293V, M357AS, E370ED, T377TMI.
Key Molecule: HIV1 Reverse transcriptase (HIV1 RT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.V35L+p.M41L+p.K43AT+p.S68G+p.L74LI+p.K103S+p.V118I+p.K122E+p.D177G+p.V179I+p.M184V+p.G190A+p.L210W+p.T215Y+p.K219KN+p.K223KQ+p.V245E+p.A272P+p.R284RK
Missense mutation 0.2 Susceptible [4]
Sensitive Drug Rilpivirine
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included V35L, M41L, K43AT, S68G, L74LI, K103S, V118I, K122E, D177G, V179I, M184V, G190A, L210W, T215Y, K219KN, K223KQ, V245E, A272P, R284RK.
Key Molecule: HIV1 Reverse transcriptase (HIV1 RT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.V35L+p.T39A+p.R83K+p.A98APS+p.D123E+p.Q174HN+p.G196E+p.T200I+p.R211RK+p.V245VM+p.D250E+p.A272P+p.K277R+p.T286A+p.P294PS+p.E297R
Missense mutation 0.5 Susceptible [4]
Sensitive Drug Rilpivirine
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included V35L, T39A, R83K, A98APS, D123E, Q174HN, G196E, T200I, R211RK, V245VM, D250E, A272P, K277R, T286A, P294PS, E297R.
Key Molecule: HIV1 Reverse transcriptase (HIV1 RT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.V35M+p.K70E+p.K102Q+p.K103N+p.D123E+p.S162C+p.K173E+p.Q174R+p.I178L+p.M184V+p.T200A+p.R211K+p.L228HR+p.M230L+p.L234I+p.V245KQ+p.K277R+p.L283I+p.V292I+p.I293V+p.Q334QR+p.G335X+p.T369TA+p.V381VI
Missense mutation 5.5 Susceptible [4]
Sensitive Drug Rilpivirine
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included V35M, K70E, K102Q, K103N, D123E, S162C, K173E, Q174R, I178L, M184V, T200A, R211K, L228HR, M230L, L234I, V245KQ, K277R, L283I, V292I, I293V, Q334QR, G335X, T369TA, V381VI.
Key Molecule: HIV1 Reverse transcriptase (HIV1 RT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.V35R+p.M41L+p.K49R+p.V60I+p.D67N+p.T69N+p.K70R+p.V108I+p.K122Q+p.I135T+p.S162D+p.D177E+p.Y181C+p.M184V+p.V189I+p.T200A+p.T215F+p.D218E+p.K219Q+p.L228R+p.V245E+p.I293V
Missense mutation 2.2 Susceptible [8]
Sensitive Drug Rilpivirine
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included V35R, M41L, K49R, V60I, D67N, T69N, K70R, V108I, K122Q, I135T, S162D, D177E, Y181C, M184V, V189I, T200A, T215F, D218E, K219Q, L228R, V245E, I293V.
Key Molecule: HIV1 Reverse transcriptase (HIV1 RT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.V35R+p.M41L+p.K49R+p.V60I+p.K64H+p.D67N+p.T69N+p.K70R+p.V108I+p.K122Q+p.I135T+p.S162D+p.D177E+p.Y181C+p.M184V+p.V189I+p.T200A+p.T215F+p.D218E+p.K219Q+p.L228R+p.V245E
Missense mutation 1.3 Susceptible [8]
Sensitive Drug Rilpivirine
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included V35R, M41L, K49R, V60I, K64H, D67N, T69N, K70R, V108I, K122Q, I135T, S162D, D177E, Y181C, M184V, V189I, T200A, T215F, D218E, K219Q, L228R, V245E.
Key Molecule: HIV1 Reverse transcriptase (HIV1 RT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.V35T+p.D67N+p.K70R+p.K103N+p.V106A+p.D123E+p.D177E+p.M184V+p.G196E+p.T200A+p.R211N+p.T215F+p.K219Q+p.K277R+p.K281X
Missense mutation 0.6 Susceptible [8]
Sensitive Drug Rilpivirine
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included V35T, D67N, K70R, K103N, V106A, D123E, D177E, M184V, G196E, T200A, R211N, T215F, K219Q, K277R, K281X.
Key Molecule: HIV1 Reverse transcriptase (HIV1 RT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.V35T+p.K43R+p.K64Y+p.D67N+p.K70R+p.L74I+p.K103S+p.V106A+p.D123E+p.D177E+p.M184V+p.G196E+p.T200A+p.R211S+p.T215F+p.K219Q+p.L228H+p.Q242H+p.K277R+p.R284K
Missense mutation 2 Susceptible [8]
Sensitive Drug Rilpivirine
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included V35T, K43R, K64Y, D67N, K70R, L74I, K103S, V106A, D123E, D177E, M184V, G196E, T200A, R211S, T215F, K219Q, L228H, Q242H, K277R, R284K.
Key Molecule: HIV1 Reverse transcriptase (HIV1 RT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.V35VI+p.R83K+p.K102Q+p.V106M+p.K122E+p.I135V+p.S162C+p.T165TI+p.Q174R+p.D177E+p.V179D+p.G196E+p.I202V+p.R211Q+p.F214L+p.A272P+p.K277R+p.L283LI+p.I293V+p.M357ML+p.I375IV
Missense mutation 0.8 Susceptible [4]
Sensitive Drug Rilpivirine
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included V35VI, R83K, K102Q, V106M, K122E, I135V, S162C, T165TI, Q174R, D177E, V179D, G196E, I202V, R211Q, F214L, A272P, K277R, L283LI, I293V, M357ML, I375IV.
Key Molecule: HIV1 Reverse transcriptase (HIV1 RT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.Y188L
Missense mutation 6 Susceptible [10]
Sensitive Drug Rilpivirine
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included Y188L.
Key Molecule: HIV1 Reverse transcriptase (HIV1 RT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.K101E+p.K102Q+p.S162C+p.K277R+p.I293V
Missense mutation 3 Susceptible [11]
p.K102Q+p.E138K+p.S162C+p.K277R+p.I293V
Missense mutation 2.3 Susceptible [11]
p.K101E+p.K102Q+p.E138K+p.S162C+p.M184I+p.K277R+p.I293V
Missense mutation 3.3 Susceptible [11]
p.K102Q+p.E138K+p.S162C+p.M184I+p.K277R+p.I293V
Missense mutation 3.2 Susceptible [11]
p.K101E+p.K102Q+p.E138K+p.S162C+p.K277R+p.I293V
Missense mutation 3.2 Susceptible [11]
Sensitive Drug Rilpivirine
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
In Vitro Model HEK293T cells Kidney Homo sapiens (Human) CVCL_0063
Experiment for
Molecule Alteration		 Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay
Mechanism Description The K101E substitution conferred large reductions in susceptibility to NVP and DLV, while more modest reductions in susceptibility to EFV, ETR, or RPV were observed. In contrast, the E138k substitution did not confer large reductions in susceptibility to any of the NNRTIs and only small reductions in susceptibility to ETR and RPV. That is because that the K101E substitution compensates for the impaired viral replication capacity of HIV-1 containing M184I.
References
Ref 1 Characterization of HIV-1 drug resistance development through week 48 in antiretroviral naive subjects on rilpivirine/emtricitabine/tenofovir DF or efavirenz/emtricitabine/tenofovir DF in the STaR study (GS-US-264-0110). J Acquir Immune Defic Syndr. 2014 Mar 1;65(3):318-26. doi: 10.1097/QAI.0000000000000017.
Ref 2 Non-nucleoside reverse transcriptase inhibitor (NNRTI) cross-resistance: implications for preclinical evaluation of novel NNRTIs and clinical genotypic resistance testing. J Antimicrob Chemother. 2014 Jan;69(1):12-20. doi: 10.1093/jac/dkt316. Epub 2013 Aug 9.
Ref 3 Comparison of the Antivirogram and PhenoSense assays to determine phenotypic susceptibility to rilpivirine in patient samples from the Phase III ECHO and THRIVE trials.
Ref 4 Standardized comparison of the relative impacts of HIV-1 reverse transcriptase (RT) mutations on nucleoside RT inhibitor susceptibilityAntimicrob Agents Chemother. 2012 May;56(5):2305-13. doi: 10.1128/AAC.05487-11. Epub 2012 Feb 13.
Ref 5 Combinations of HIV-1 reverse transcriptase mutations L100I+K103N/S and L100I+K103R+V179D reduce susceptibility to rilpivirine.
Ref 6 Panel of prototypical recombinant infectious molecular clones resistant to nevirapine, efavirenz, etravirine, and rilpivirineAntimicrob Agents Chemother. 2012 Aug;56(8):4522-4. doi: 10.1128/AAC.00648-12. Epub 2012 Jun 4.
Ref 7 Genotypic predictors of human immunodeficiency virus type 1 drug resistanceProc Natl Acad Sci U S A. 2006 Nov 14;103(46):17355-60. doi: 10.1073/pnas.0607274103. Epub 2006 Oct 25.
Ref 8 Phenotypic evidence for NRTI resistance in HIV-1 isolates with the RT mutation K64H.
Ref 9 The HIV-1 reverse transcriptase M184I mutation enhances the E138K-associated resistance to rilpivirine and decreases viral fitnessJ Acquir Immune Defic Syndr. 2012 Jan 1;59(1):47-54. doi: 10.1097/QAI.0b013e31823aca74.
Ref 10 Mutation Y188L of HIV-1 reverse transcriptase is strongly associated with reduced susceptibility to rilpivirine
Ref 11 Role of the K101E substitution in HIV-1 reverse transcriptase in resistance to rilpivirine and other nonnucleoside reverse transcriptase inhibitors. Antimicrob Agents Chemother. 2013 Nov;57(11):5649-57. doi: 10.1128/AAC.01536-13. Epub 2013 Sep 3.

If you find any error in data or bug in web service, please kindly report it to Dr. Sun and Dr. Zhang.